- The shares of life sciences firm Applied DNA Sciences ( NASDAQ: APDN ) gained ~17% in the morning hours Friday after the company announced the regulatory submissions made to the New York State Department of Health (NYSDOH) for full approval of its monkeypox test.
- APDN's clinical laboratory subsidiary, Applied DNA Clinical Labs (ADCL), has submitted the validation package seeking full approval for the monkeypox test as a form NYSDOH Laboratory Developed Test (LDT).
- The NYSDOH approval is expected to support ADCL's monkeypox testing services at its CLEP/CLIA molecular diagnostics laboratory in Stony Brook, N.Y.
- In Jan. 2022, NYSDOH issued conditional approval for ADCL's Linea 2.0 COVID-19 Assay as an LDT.
For further details see:
Applied DNA adds 17% as company seeks approval for monkeypox test in New York